FOLH1 and prostate carcinoma: Following a single treatment with [161Tb]Tb-PSMA-617, one patient with advanced metastatic castration-resistant prostate cancer exhibited impressive partial remission, even with disease progression following extensive [177Lu]Lu-PSMA-617 therapy [35].